Teva, Orchid Settle Patent Dispute Over Azilect

Law360, Los Angeles (April 30, 2013, 8:56 PM EDT) -- Teva Pharmaceutical Industries Ltd. and Orchid Chemicals & Pharmaceuticals Ltd. have reached a settlement in patent and antitrust litigation over Teva’s Parkinson’s disease drug Azilect, resulting in dismissal of all claims and counterclaims between the two companies, according to documents filed in New Jersey federal court Tuesday.

The settlement comes two months after Teva slammed the antitrust and patent invalidity claims raised by generic drugmakers Watson Laboratories Inc., Mylan Pharmaceuticals Inc., Apotex Corp. and Orchid, saying there is clear evidence that they infringed Teva’s patent for...
To view the full article, register now.